Outset Medical (NASDAQ:OM) Upgraded at Wall Street Zen

Outset Medical (NASDAQ:OM) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other brokerages have also recently weighed in on OM. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. Stifel Nicolaus dropped their price target on Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 7th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $7.00 target price on shares of Outset Medical in a research report on Wednesday, December 17th. Finally, BTIG Research decreased their target price on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Outset Medical Price Performance

Shares of NASDAQ:OM opened at $3.56 on Friday. The company has a quick ratio of 5.40, a current ratio of 6.67 and a debt-to-equity ratio of 0.76. The firm has a market capitalization of $65.18 million, a PE ratio of -0.52 and a beta of 2.12. Outset Medical has a twelve month low of $3.00 and a twelve month high of $21.98. The company has a 50-day moving average price of $3.98 and a two-hundred day moving average price of $7.23.

Insider Activity

In other Outset Medical news, General Counsel John L. Brottem sold 9,314 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total value of $47,687.68. Following the completion of the sale, the general counsel directly owned 36,957 shares in the company, valued at $189,219.84. This trade represents a 20.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Marc Nash sold 5,375 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $27,520.00. Following the completion of the sale, the executive vice president owned 42,785 shares of the company’s stock, valued at $219,059.20. This trade represents a 11.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 40,910 shares of company stock valued at $193,040. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. BML Capital Management LLC bought a new stake in shares of Outset Medical during the 4th quarter valued at $2,015,000. Pura Vida Investments LLC boosted its position in shares of Outset Medical by 8,482.4% in the 2nd quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock worth $8,243,000 after purchasing an additional 424,120 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Outset Medical in the 3rd quarter worth approximately $5,324,000. Geode Capital Management LLC grew its stake in shares of Outset Medical by 955.9% in the 2nd quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock worth $7,984,000 after buying an additional 376,196 shares during the last quarter. Finally, Millennium Management LLC grew its stake in shares of Outset Medical by 165.8% in the 3rd quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock worth $5,950,000 after buying an additional 262,874 shares during the last quarter.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.